# OnCo record keynote-641 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-641/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-641", "NCT03834493" ;
  schema:name "KEYNOTE-641"@en ;
  schema:alternateName "KEYNOTE-641"@en, "MK-3475-641"@en ;
  schema:description "Adding pembrolizumab to enzalutamide did not help. The trial was stopped for futility, and three times as many men had a serious side effect."@en ;
  schema:url <https://onco.cc/trials/keynote-641/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03834493>, <https://doi.org/10.1016/j.annonc.2025.05.007> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/enzalutamide/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/arpi/> ;
  onco:trials <https://onco.cc/trials/imbassador250/>, <https://onco.cc/trials/keynote-921/>, <https://onco.cc/trials/keynote-991/> .